Emergen Research continues to strengthen its position in the market intelligence space by introducing its advanced Dry Eye Syndrome Treatment market research content, designed to help organizations navigate complex and evolving business environments. This newly developed content library focuses on delivering meaningful insights that allow businesses to improve decision-making and identify long-term growth opportunities across multiple industries.
The global Dry Eye Syndrome Treatment market size is expected to grow from 7.6 billion by the end of 2025 to 14.0 billion by 2035, registering a revenue CAGR of 7.00% during the forecast period. The major Dry Eye Syndrome Treatment market growth factors are the rising prevalence of dry eye disease, increase in awareness regarding the condition, and improvements in treatment modalities. Dry eye syndrome is basically a public health problem that affects a huge number of people in the world, especially those in their old age and those being digital screen addicts.
According to the World Health Organization (WHO), by the year 2030, there would be one person out of 6 worldwide aged 60 years or older, up from 1 billion at present in 2020 to 1.4 billion. The shift in this demographic category of older adults would be more significant in low- and middle-income countries since it is expected that by 2050, 80% of all older adults would be residing in such countries. It is also projected that the number of individuals aged 80-plus will triple, rising from 142 million in 2020 to 426 million in 2050.
Factors such as air pollution, hormonal changes, and certain medications also contribute to the likelihood of increasing dry eye disease. The demand for newer treatments for dry eye disease, including prescription medications, over-the-counter eye drops, and surgical procedures for the treatment of dry eye syndrome, has also been increasing as more effective solutions to manage their symptoms arrive at the market. Furthermore, the expanded adoption of advanced diagnostic devices as well as personalized treatment plans is boosting the growth of the market.
The competitive Dry Eye Syndrome Treatment market is identified by the presence of various key players such as Allergan, Santen Pharmaceutical, Novartis, Johnson & Johnson, and Oculis Holding AG, all of which are striving for innovation and broadening product portfolios. For instance, in June 2025, Oculis Holding AG announced good topline results from its Phase 2b RELIEF trial of licaminlimab, an anti-TNFα biologic eye drop for dry eye disease (DED).
Licaminlimab is an anti-TNFα biologic eye drop for dry eye disease (DED). The trial included 122 patients, some with a TNFR1-related genotype, and showed treatment efficacy in terms of safety during six weeks. This data would indicate licaminlimab as a promising option for treating DED. Moderate fragmentation exists in the market, with pharmaceutical businesses and medical device manufacturers competing for market share. The market is dominated by North America and Europe due to the higher cases of dry eye syndrome, better healthcare infrastructure, and even more avenues to reach advanced treatments. Meanwhile, the Asia Pacific region is projected to experience the fastest growth, mainly because of increasing urbanization, rising awareness, and improving healthcare access in emerging economies. As the market evolves, companies are investing in R&D to develop more effective treatments and address unmet patient needs.
One of the most valuable aspects of this research is its strong emphasis on continuous updates and relevance. In today’s fast-changing market conditions, relying on outdated information can lead to poor strategic decisions. Emergen Research ensures that its content reflects the latest developments, trends, and industry shifts, allowing businesses to stay competitive and adapt their strategies effectively over time.
The research content is structured in a way that simplifies complex data and presents it in an easily understandable format. Instead of overwhelming users with excessive information, the report focuses on clarity and usability. This approach makes it suitable for a wide range of stakeholders, including investors, business owners, consultants, and policymakers who require actionable insights without unnecessary complexity.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4990
Another important strength of the report lies in its ability to deliver expert-driven insights. The analysts behind the Dry Eye Syndrome Treatment market research content bring years of experience and industry expertise, enabling them to interpret data accurately and highlight meaningful trends. Their insights help businesses understand not only what is happening in the market but also the reasons behind these changes, making it easier to plan future strategies.
Market segmentation:-
The report also provides a detailed evaluation of market segmentation, which plays a critical role in understanding industry structure. By examining different product types, applications, and end-user industries, the study helps businesses identify key areas of demand and growth potential. This segmentation allows organizations to focus their efforts on the most promising segments and allocate resources more efficiently.
Market competition in the global Dry Eye Syndrome Treatment industry is characterized by the presence of global and regional players such as Allergan, Santen Pharmaceutical, Novartis, Johnson & Johnson, and others. The global dry eye syndrome treatment market is relatively fragmented with a high level of competition. Companies compete based on product innovation, the effectiveness of treatments, and brand recognition. The market also witnesses players developing a wide range of solutions for various types of dry eye disease, including aqueous deficient and evaporative dry eye.
With an emphasis on research and development, companies are focused on launching new therapies and devices, particularly those offering long-term relief and improved patient outcomes. In addition, collaborations, partnerships, and mergers are commonly used strategies to enhance market share and expand geographically. North America and Europe are currently the dominant regions, with strong market presence, while emerging economies in Asia Pacific are expected to experience rapid growth. Despite the competition, a few key players maintain leadership due to their established product portfolios and strong customer loyalty.
In October 2025, Novaliq and Laboratoires Théa announced that Vevizye, a treatment for dry eye disease in adults, received approval from the European Commission. This makes Vevizye the first and only water-free ciclosporin 0.1% eye drop solution to gain approval in Europe.
Some of the key companies in the global Dry Eye Syndrome Treatment Market include:
- Allergan
- Santen Pharmaceutical
- Novartis
- Johnson & Johnson
- Bausch + Lomb
- Regeneron Pharmaceuticals
- Oyster Point Pharma
- TearLab Corporation
- Ursapharm Arzneimittel
- TheraTears
In addition to segmentation, the report offers valuable recommendations that businesses can apply directly to their operations. These recommendations are designed to enhance product development, improve service delivery, and strengthen overall market positioning. By focusing on practical outcomes, Emergen Research ensures that the research goes beyond theoretical analysis and provides real value to its users.
The Dry Eye Syndrome Treatment market research content includes a wide variety of resources such as detailed reports, case studies, whitepapers, and trend analyses. These materials cover multiple sectors, including technology, healthcare, finance, consumer goods, and manufacturing, making the content highly versatile and relevant for different industries.
Competitive landscape:-
A comprehensive analysis of the competitive landscape is another key feature of the report. Understanding competition is essential for businesses aiming to maintain or improve their market position. The study examines major players in the Dry Eye Syndrome Treatment market and provides insights into their strategies, product portfolios, and recent developments. Activities such as mergers, acquisitions, partnerships, and technological innovations are analyzed to give a clear picture of the competitive environment.
Rising prevalence of dry eye disease due to aging and lifestyle factors
The rising prevalence of dry eye disease is a significant driver for the global Dry Eye Syndrome Treatment market. According to the WHO, approximately 2.2 billion people experience vision impairment globally with refractive errors and cataracts being the leading causes. Notably, 1 billion cases of vision impairment could have been prevented or remain unaddressed. Vision impairment poses a significant economic burden, with global productivity losses estimated at $411 billion annually.
As the global population ages, the incidence of dry eye disease is increasing, particularly among older adults. Age-related changes in tear production and the natural degradation of the ocular surface contribute to this trend. Additionally, lifestyle factors such as prolonged screen time, air pollution, and increased use of contact lenses are exacerbating the condition.
More people are experiencing symptoms such as dryness, irritation, and blurred vision, prompting a growing demand for effective treatments. As awareness about the condition increases, individuals are seeking early diagnosis and intervention, further driving market growth. The rise in digital eye strain from long hours in front of screens has also significantly contributed to the increasing prevalence of dry eye syndrome.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/dry-eye-syndrome-treatment-market
The report also highlights the importance of data-driven decision-making in today’s business world. Organizations that rely on accurate data and insights are better equipped to identify opportunities and minimize risks. By combining qualitative and quantitative analysis, Emergen Research ensures that businesses have access to reliable and well-rounded information.
Another key element of the research is its focus on understanding consumer behavior and market trends. By analyzing how consumer preferences are evolving, businesses can adjust their strategies to meet changing demands. This insight is particularly valuable in industries where customer expectations play a significant role in shaping market dynamics.
The Dry Eye Syndrome Treatment market research content is designed to serve a diverse audience. From small and medium-sized enterprises to large corporations, as well as research organizations and consulting firms, the report provides valuable insights for all stakeholders. Government bodies and regulatory authorities can also use the information to support policy-making and industry development.
In addition to providing insights, the report focuses on helping businesses build a competitive advantage. By identifying untapped opportunities and emerging trends, organizations can position themselves more effectively in the market. This proactive approach enables businesses to stay ahead of competitors and achieve sustainable growth.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4990
About Emergen Research
Emergen Research is a leading market research and consulting firm that provides syndicated reports, customized research solutions, and strategic advisory services. The company is dedicated to helping clients understand market dynamics, analyze consumer behavior, and make informed business decisions through accurate and data-driven insights.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.co